Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pragmatic intervention for increasing self-directed exercise behaviour and improving important health outcomes in people with multiple sclerosis: a randomised controlled trial.
Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis.
Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).
Validity and reliability of Persian version of Modified Fatigue Impact Scale (MFIS) questionnaire in Iranian patients with multiple sclerosis.
[Magnetic reasonance spectroscopy-guided stereotactic biopsy for brain lesion].
3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS.
New methods for multiple sclerosis drug discovery.
LOGISMOS-B: Layered Optimal Graph Image Segmentation of Multiple Objects and Surfaces for the Brain.
Mapi Pharma granted United States patent covering the process for the preparation of fingolimod for multiple sclerosis
Substance Name: ONO 4641
Restless legs syndrome heralding an acute exacerbation of multiple sclerosis.
2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties.
Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study.
Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis.
Selective ultrastructural vulnerability in the cuprizone-induced experimental demyelination.
Comparison of patient-reported outcome measures in multiple sclerosis.
Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity.
Cognitive reserve and patient-reported outcomes in multiple sclerosis.
Bioinformatics challenges for genome-wide association studies.
Could behavioral therapies target specific deficits in multiple sclerosis patients?
JC virus Reactivation During Prolonged Natalizumab Monotherapy for Multiple Sclerosis.
Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.
Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis.
Multiple sclerosis: Oral BG12 for treatment of relapsing-remitting MS.
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions.

Pages